Alumni Ventures Group
Alumni Ventures Group is a venture capital firm based in Manchester, New Hampshire, with offices across North America. It provides access to venture investing for individual accredited investors, particularly alumni networks, by offering diversified portfolios of venture opportunities and allowing members to invest alongside fellow alumni in ventures led by peers. The firm backs early-stage and later-stage opportunities across technology, consumer, healthcare, financial services, and other sectors, with a sector- and geography-agnostic approach. It typically invests between $10,000 and $3 million per deal and emphasizes the involvement of alumni connections and an institutional lead investor in opportunities. Alumni Ventures also offers focused funds to broaden participation, enabling accredited investors to access venture portfolios diversified by type, sector, stage, and geography. The model aims to democratize access to venture capital while maintaining rigorous selection standards through alumni networks.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Genetics
Q Bio
Venture Round in 2024
Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.
caVos biotherapeutics
Seed Round in 2024
An emerging genomic and data science company, developing novel drugs based on naturally occurring resistance mechanisms
ParcelBio
Seed Round in 2024
ParcelBio is a biotechnology company specializing in the development of a novel, programmable method for safely and precisely delivering messenger RNA (mRNA) to diverse cell types within the body. Their technology aims to create targeted, potent, and durable RNA therapeutics, with the potential to treat a wide range of diseases, including cancer, genetic disorders, and infectious diseases.
HelixNano
Series A in 2024
HelixNano is a biotechnology startup that employs artificial intelligence and synthetic biology to develop innovative treatments for genetic diseases. Founded with backing from Y Combinator and venture capitalists, the company initially focused on creating cancer vaccines over two years. Currently, HelixNano is adapting its technology to combat COVID-19, aiming to produce precise and safe vaccine candidates. Its long-term goal is to develop a universal coronavirus vaccine that protects against future outbreaks.
Anthology
Pre Seed Round in 2023
Anthology is an evolution company that generates diverse genomes to scale and digitalize biomanufacturing.
Eigen Therapeutics
Seed Round in 2023
Eigen Therapeutics is a biotechnology company dedicated to advancing cancer treatment through the development of innovative therapies. It specializes in "priming" therapies that enhance the effectiveness of targeted treatments by addressing cancer heterogeneity, which makes cancer cells more susceptible to therapeutic interventions while simultaneously protecting healthy cells. Eigen is creating a high-throughput discovery platform that integrates proprietary machine learning algorithms to identify novel drug classes and therapeutic approaches capable of altering a cell’s state to increase vulnerability to treatments. This platform combines biology and engineering, utilizing in-house developed robotic systems, laboratory operations software, and machine learning analysis pipelines. The company's mission focuses on improving patient outcomes by providing novel combination therapeutics that enhance efficacy and reduce toxicity in cancer care, ultimately aiming to meet significant medical needs in oncology.
3X Genetics
Pre Seed Round in 2023
3X Genetics is a company focused on developing medical screening solutions aimed at identifying genetic disorders, particularly in infants and children. The company has created innovative technologies that allow for proactive screening of the population for conditions such as myotonic dystrophy and other trinucleotide repeat issues associated with progressive muscle weakness. By enabling healthcare professionals to detect these genetic disorders early, 3X Genetics plays a crucial role in preventing the birth of children affected by serious genetic diseases.
Eigen Therapeutics
Seed Round in 2022
Eigen Therapeutics is a biotechnology company dedicated to advancing cancer treatment through the development of innovative therapies. It specializes in "priming" therapies that enhance the effectiveness of targeted treatments by addressing cancer heterogeneity, which makes cancer cells more susceptible to therapeutic interventions while simultaneously protecting healthy cells. Eigen is creating a high-throughput discovery platform that integrates proprietary machine learning algorithms to identify novel drug classes and therapeutic approaches capable of altering a cell’s state to increase vulnerability to treatments. This platform combines biology and engineering, utilizing in-house developed robotic systems, laboratory operations software, and machine learning analysis pipelines. The company's mission focuses on improving patient outcomes by providing novel combination therapeutics that enhance efficacy and reduce toxicity in cancer care, ultimately aiming to meet significant medical needs in oncology.
American Gene Technologies International
Series D in 2022
American Gene Technologies International is a gene and cell therapeutics company developing a lentiviral platform for broad applications across infectious diseases, immuno-oncology, monogenic disorders, and regenerative medicine. It pursues HIV cure strategies, including a lead candidate for functional cure, and an immuno-oncology approach that stimulates gamma-delta T cells to target solid tumors. The company also develops a therapeutic approach for Phenylketonuria by expressing phenylalanine hydroxylase, using proprietary viral vector and gene therapy technologies. Founded in 2007 and based in Rockville, Maryland, AGT focuses on translating its platform into therapies that aim to cure diseases rather than merely treat them.
GRO Biosciences
Series A in 2021
GRO Biosciences employs computational protein design and synthetic biology to enhance protein therapeutics. It has developed multiple genomically recoded bacterial strains capable of incorporating non-standard amino acids into proteins, resulting in improved potency, stability, and targeted delivery. The company focuses on developing advanced treatments for diabetes, growth disorders, and autoimmunity.
miRecule
Venture Round in 2021
miRecule is a biotechnology company developing targeted RNA therapies for cancer and muscular dystrophy. It uses its proprietary DREAmiR platform to analyze genomic data from thousands of patients, identifying genetic abnormalities and creating tailored RNA therapeutics to directly address these issues.
Mission Bio
Venture Round in 2020
Mission Bio develops and delivers tools for studying cellular heterogeneity in human health and life science research. Its flagship product is the Tapestri Platform, a single-cell platform that detects DNA and protein changes, enabling precise detection of heterogeneity in disease progression and treatment response. The company's solutions are primarily applied in oncology, including blood cancers and solid tumors.
Excision BioTherapeutics
Venture Round in 2019
Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company is dedicated to the development and commercialization of gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company's mission is to advance these therapeutics into safe and effective treatments, significantly improving the lives of individuals affected by viral infections globally.
miRecule
Venture Round in 2019
miRecule is a biotechnology company developing targeted RNA therapies for cancer and muscular dystrophy. It uses its proprietary DREAmiR platform to analyze genomic data from thousands of patients, identifying genetic abnormalities and creating tailored RNA therapeutics to directly address these issues.
Motif
Series A in 2019
Motif FoodWorks, Inc. is a bio-organism engineering company based in Boston, Massachusetts, that specializes in developing innovative food ingredients. The company focuses on producing animal-free proteins, including meat alternatives and dairy-free proteins, catering to the growing demand for plant-based food solutions. By utilizing fermentation technology, Motif creates essential proteins and nutrients that enhance both nutrition and flavor in food products. The company collaborates with chefs, health experts, and food innovators to develop new ingredient solutions aimed at transforming the food industry and promoting sustainability. Established in 2018 and originally known as Motif Ingredients, Motif FoodWorks rebranded in 2019 to reflect its commitment to advancing the next generation of healthy and plant-based foods.
Clear Labs
Series B in 2018
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
American Gene Technologies International
Series D in 2018
American Gene Technologies International is a gene and cell therapeutics company developing a lentiviral platform for broad applications across infectious diseases, immuno-oncology, monogenic disorders, and regenerative medicine. It pursues HIV cure strategies, including a lead candidate for functional cure, and an immuno-oncology approach that stimulates gamma-delta T cells to target solid tumors. The company also develops a therapeutic approach for Phenylketonuria by expressing phenylalanine hydroxylase, using proprietary viral vector and gene therapy technologies. Founded in 2007 and based in Rockville, Maryland, AGT focuses on translating its platform into therapies that aim to cure diseases rather than merely treat them.
Celularity
Venture Round in 2017
Celularity is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies targeting various diseases, including cancer, infectious, and degenerative conditions.
Clear Labs
Series B in 2016
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.